The role of B cells in multiple sclerosis: Implications for B-cell-targeted therapy

Current Medicinal Chemistry

Volumn 17, Issue 28, 2010, Pages 3215-3222

  Hirotani, M ^a   Niino, M ^a   Sasaki, H ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibody; B cells; Complement activation; Multiple sclerosis; Rituximab

Indexed keywords

ANTIBODY; BETA INTERFERON; GLATIRAMER; GLUCOCORTICOID; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; METHOTREXATE; MITOXANRONE; MYELIN ANTIBODY; NATALIZUMAB; OFATUMUMAB; PLACEBO; RITUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AUTOANTIBODY; COMPLEMENT; MONOCLONAL ANTIBODY;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL FUNCTION; CELL INTERACTION; CELL LINEAGE; CELL THERAPY; CENTRAL NERVOUS SYSTEM; COMPLEMENT ACTIVATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; HODGKIN DISEASE; HUMAN; IMMUNOGLOBULIN PRODUCTION; INFECTION; LEUKOENCEPHALOPATHY; LYMPHOID CELL; MENINX; MOLECULARLY TARGETED THERAPY; MULTIFOCAL LEUCOENCEPHALOPATHY; MULTIPLE SCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VASCULITIS; DRUG EFFECT; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; B-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; COMPLEMENT SYSTEM PROTEINS; HUMANS; INTERLEUKIN-10; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 79952201233     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986710792231969     Document Type: Review

References (101)

1. Owens, G. P.; Bennett, J. L.; Gilden, D. H.; Burgoon, M. P. The B cell response in multiple sclerosis. Neurol. Res., 2006, 28(3), 236-244. (Pubitemid 43765106)
2. Prineas, J. W.; Wright, R. G. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest., 1978, 38(4), 409-421. (Pubitemid 8338235)
3. Archelos, J. J.; Storch, M. K.; Hartung, H. P. A. The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol., 2000, 47(6), 694-706. (Pubitemid 30390190)
4. Esiri, M. M. Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet, 1977, 2(8036), 478.
5. Ozawa, K.; Suchanek, G.; Breitschopf, H.; Bruck, W.; Budka, H.; Jellinger, K.; Lassmann, H. Patterns of oligodendroglia pathology in multiple sclerosis. Brain, 1994, 117(Pt 6), 1311-1322.
6. Todd, D. J.; Helfgott, S. M. Serum sickness following treatment with rituximab. J. Rheumatol., 2007, 34(2), 430-433.
7. Storch, M. K.; Piddlesden, S.; Haltia, M.; Iivanainen, M.; Morgan, P.; Lassmann, H. Multiple sclerosis: in situ evidence for antibodyand complement-mediated demyelination. Ann. Neurol., 1998, 43(4), 465-471. (Pubitemid 28231721)
8. Oh, S.; Cudrici, C.; Ito, T.; Rus, H. B-cells and humoral immunity in multiple sclerosis. Implications for therapy. Immunol. Res., 2008, 40(3), 224-234. (Pubitemid 351903819)
9. Prineas, J. W.; Graham, J. S. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann. Neurol., 1981, 10(2), 149-158. (Pubitemid 11053101)
10. Genain, C. P.; Cannella, B.; Hauser, S. L.; Raine, C. S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med., 1999, 5(2), 170-175. (Pubitemid 29068523)
11. Wucherpfennig, K. W.; Catz, I.; Hausmann, S.; Strominger, J. L.; Steinman, L.; Warren, K. G. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J. Clin. Invest., 1997, 100(5), 1114-1122. (Pubitemid 27386295)
12. Niehaus, A.; Shi, J.; Grzenkowski, M.; Diers-Fenger, M.; Archelos, J.; Hartung, H. P.; Toyka, K.; Bruck, W.; Trotter, J. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann. Neurol., 2000, 48(3), 362-371.
13. Walsh, M. J.; Murray, J. M. Dual implication of 2', 3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis. J. Clin. Invest., 1998, 101(9), 1923-1931. (Pubitemid 28226112)
14. Hauser, S. L.; Waubant, E.; Arnold, D. L.; Vollmer, T.; Antel, J.; Fox, R. J.; Bar-Or, A.; Panzara, M.; Sarkar, N.; Agarwal, S.; Langer-Gould, A.; Smith, C. H.; Group, H. T. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med., 2008, 358(7), 676-688. (Pubitemid 351240747)
15. Stangel, M.; Toyka, K. V.; Gold, R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch. Neurol., 1999, 56(6), 661-663. (Pubitemid 29266463)
16. Aloisi, F.; Pujol-Borrell, R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol., 2006, 6(3), 205-217. (Pubitemid 43290990)
17. Magliozzi, R.; Howell, O.; Vora, A.; Serafini, B.; Nicholas, R.; Puopolo, M.; Reynolds, R.; Aloisi, F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain, 2007, 130(Pt 4), 1089-1104. (Pubitemid 47355604)
18. Prineas, J. W. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science, 1979, 203(4385), 1123-1125. (Pubitemid 9148091)
19. Duddy, M.; Niino, M.; Adatia, F.; Hebert, S.; Freedman, M.; Atkins, H.; Kim, H. J.; Bar-Or, A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol., 2007, 178(10), 6092-6099. (Pubitemid 46717389)
20. Kabat, E. A.; Freedman, D. A.; Murray, J. P.; Knaub, V. A study of the crystalline albumin, gamma globulin and total protein in the cerebrospinal fluid of 100 cases of multiple sclerosis and in other diseases. Am. J. Med. Sci., 1950, 219(1), 55-64.
21. Cross, A. H.; Trotter, J. L.; Lyons, J. B cells and antibodies in CNS demyelinating disease. J. Neuroimmunol., 2001, 112(1-2), 1-14.
22. Archelos, J. J.; Hartung, H. P. Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci., 2000, 23(7), 317-327. (Pubitemid 30387047)
23. Lucchinetti, C.; Bruck, W.; Parisi, J.; Scheithauer, B.; Rodriguez, M.; Lassmann, H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol., 2000, 47(6), 707-717. (Pubitemid 30390191)
24. Hafler, D. A.; Slavik, J. M.; Anderson, D. E.; O'Connor, K. C.; De Jager, P.; Baecher-Allan, C. Multiple sclerosis. Immunol. Rev., 2005, 204, 208-231. (Pubitemid 40460504)
25. Martinelli, V.; Comi, G.; Filippi, M.; Poggi, A.; Colombo, B.; Rodegher, M.; Scotti, G.; Triulzi, F.; Canal, N. Paraclinical tests in acute-onset optic neuritis: basal data and results of a short followup. Acta Neurol. Scand., 1991, 84(3), 231-236.
26. Cross, A. H.; Stark, J. L. Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Immunol. Res., 2005, 32(1-3), 85-97. (Pubitemid 41153616)
27. Fraussen, J.; Vrolix, K.; Martinez-Martinez, P.; Losen, M.; De Baets, M. H.; Stinissen, P.; Somers, V. B cell characterization and reactivity analysis in multiple sclerosis. Autoimmun. Rev., 2009, 8(8), 654-658.
28. Siritho, S.; Freedman, M. S. The prognostic significance of cerebrospinal fluid in multiple sclerosis. J. Neurol. Sci., 2009, 279(1-2), 21-25.
29. Lafaille, J. J.; Nagashima, K.; Katsuki, M.; Tonegawa, S. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell, 1994, 78(3), 399-408. (Pubitemid 24250805)
30. Poser, C. M.; Brinar, V. V. The accuracy of prevalence rates of multiple sclerosis: a critical review. Neuroepidemiology, 2007, 29(3-4), 150-155. (Pubitemid 351197516)
31. Tumani, H.; Tourtellotte, W. W.; Peter, J. B.; Felgenhauer, K. Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. The Optic Neuritis Study Group. J. Neurol. Sci., 1998, 155(1), 44-49. (Pubitemid 28141057)
32. Frederiksen, J. L.; Larsson, H. B.; Olesen, J. Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis. Acta Neurol. Scand., 1992, 86(3), 317-322.
33. Masjuan, J.; Alvarez-Cermeno, J. C.; Garcia-Barragan, N.; Diaz-Sanchez, M.; Espino, M.; Sadaba, M. C.; Gonzalez-Porque, P.; Martinez San Millan, J.; Villar, L. M. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology, 2006, 66(4), 576-578. (Pubitemid 43739891)
34. Villar, L. M.; Masjuan, J.; Gonzalez-Porque, P.; Plaza, J.; Sadaba, M. C.; Roldan, E.; Bootello, A.; Alvarez-Cermeno, J. C. Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology, 2002, 58(5), 824-826. (Pubitemid 34211568)
35. Zeman, A. Z.; Kidd, D.; McLean, B. N.; Kelly, M. A.; Francis, D. A.; Miller, D. H.; Kendall, B. E.; Rudge, P.; Thompson, E. J.; McDonald, W. I. A study of oligoclonal band negative multiple sclerosis. J. Neurol. Neurosurg. Psychiatry, 1996, 60(1), 27-30. (Pubitemid 26013190)
36. Xiao, B. G.; Linington, C.; Link, H. Antibodies to myelinoligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J. Neuroimmunol., 1991, 31(2), 91-96.
37. Racke, M. K. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr. Opin. Neurol., 2008, 21(Suppl 1), S9-S18. (Pubitemid 351483538)
38. von Budingen, H. C.; Tanuma, N.; Villoslada, P.; Ouallet, J. C.; Hauser, S. L.; Genain, C. P. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. J. Clin. Immunol., 2001, 21(3), 155-170. (Pubitemid 32434302)
39. Cruz, M.; Olsson, T.; Ernerudh, J.; Hojeberg, B.; Link, H. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology, 1987, 37(9), 1515-1519. (Pubitemid 17132333)
40. Cortese, I.; Tafi, R.; Grimaldi, L. M.; Martino, G.; Nicosia, A.; Cortese, R. Identification of peptides specific for cerebrospinal fluid antibodies in multiple sclerosis by using phage libraries. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(20), 11063-11067. (Pubitemid 26333118)
41. Compston, D. A.; Morgan, B. P.; Campbell, A. K.; Wilkins, P.; Cole, G.; Thomas, N. D.; Jasani, B. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol. Appl. Neurobiol., 1989, 15(4), 307-316. (Pubitemid 19208151)
42. Barnett, M. H.; Prineas, J. W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol., 2004, 55(4), 458-468. (Pubitemid 38391962)
43. Brink, B. P.; Veerhuis, R.; Breij, E. C.; van der Valk, P.; Dijkstra, C. D.; Bo, L. The pathology of multiple sclerosis is locationdependent: no significant complement activation is detected in purely cortical lesions. J. Neuropathol. Exp. Neurol., 2005, 64(2), 147-155. (Pubitemid 40349313)
44. Sanders, M. E.; Alexander, E. L.; Koski, C. L.; Shin, M. L.; Sano, Y.; Frank, M. M.; Joiner, K. A. Terminal complement complexes (SC5b-9) in cerebrospinal fluid in autoimmune nervous system diseases. Ann. N. Y. Acad. Sci., 1988, 540, 387-388. (Pubitemid 19115361)
45. Sellebjerg, F.; Jaliashvili, I.; Christiansen, M.; Garred, P. Intrathecal activation of the complement system and disability in multiple sclerosis. J. Neurol. Sci., 1998, 157(2), 168-174. (Pubitemid 28218560)
46. Serafini, B.; Rosicarelli, B.; Magliozzi, R.; Stigliano, E.; Aloisi, F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol., 2004, 14(2), 164-174. (Pubitemid 38656388)
47. Barone, F.; Bombardieri, M.; Rosado, M. M.; Morgan, P. R.; Challacombe, S. J.; De Vita, S.; Carsetti, R.; Spencer, J.; Valesini, G.; Pitzalis, C. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J. Immunol. 2008, 180(7), 5130-5140.
48. Meraouna, A.; Cizeron-Clairac, G.; Panse, R. L.; Bismuth, J.; Truffault, F.; Tallaksen, C.; Berrih-Aknin, S. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood, 2006, 108(2), 432-440. (Pubitemid 44061339)
49. Mizoguchi, A.; Mizoguchi, E.; Takedatsu, H.; Blumberg, R. S.; Bhan, A. K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity, 2002, 16(2), 219-230. (Pubitemid 34211962)
50. Krumbholz, M.; Theil, D.; Cepok, S.; Hemmer, B.; Kivisakk, P.; Ransohoff, R. M.; Hofbauer, M.; Farina, C.; Derfuss, T.; Hartle, C.; Newcombe, J.; Hohlfeld, R.; Meinl, E. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain, 2006, 129(Pt 1), 200-211. (Pubitemid 43063771)
51. Aloisi, F.; Columba-Cabezas, S.; Franciotta, D.; Rosicarelli, B.; Magliozzi, R.; Reynolds, R.; Ambrosini, E.; Coccia, E.; Salvetti, M.; Serafini, B. Lymphoid chemokines in chronic neuroinflammation. J. Neuroimmunol., 2008, 198(1-2), 106-112.
52. Baumgarth, N. A two-phase model of B-cell activation. Immunol. Rev., 2000, 176, 171-180.
53. McHeyzer-Williams, L. J.; McHeyzer-Williams, M. G. Antigenspecific memory B cell development. Annu. Rev. Immunol., 2005, 23, 487-513.
54. Harris, D. P.; Haynes, L.; Sayles, P. C.; Duso, D. K.; Eaton, S. M.; Lepak, N. M.; Johnson, L. L.; Swain, S. L.; Lund, F. E. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol., 2000, 1(6), 475-482.
55. Schultze, J. L.; Michalak, S.; Lowne, J.; Wong, A.; Gilleece, M. H.; Gribben, J. G.; Nadler, L. M. Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses. J. Exp. Med., 1999, 189(1), 1-12.
56. Wolf, S. D.; Dittel, B. N.; Hardardottir, F.; Janeway, C. A. Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med., 1996, 184(6), 2271-2278. (Pubitemid 27023727)
57. Fillatreau, S.; Sweenie, C. H.; McGeachy, M. J.; Gray, D.; Anderton, S. M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol., 2002, 3(10), 944-950. (Pubitemid 35154008)
58. Eisenberg, R.; Looney, R. J. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin. Immunol., 2005, 117(3), 207-213. (Pubitemid 43005207)
59. Hultin, L. E.; Hausner, M. A.; Hultin, P. M.; Giorgi, J. V. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry, 1993, 14(2), 196-204. (Pubitemid 23042743)
60. Levesque, M. C.; St Clair, E. W. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J. Allergy Clin. Immunol., 2008, 121(1), 13-21; quiz 22-3.
61. Tedder, T. F.; Engel, P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today, 1994, 15(9), 450-454. (Pubitemid 24272191)
62. Di Gaetano, N.; Cittera, E.; Nota, R.; Vecchi, A.; Grieco, V.; Scanziani, E.; Botto, M.; Introna, M.; Golay, J. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol., 2003, 171(3), 1581-1587. (Pubitemid 36900094)
63. Martin, F.; Chan, A. C. B cell immunobiology in disease: evolving concepts from the clinic. Annu. Rev. Immunol., 2006, 24, 467-496.
64. Cross, A. H.; Stark, J. L.; Lauber, J.; Ramsbottom, M. J.; Lyons, J. A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol., 2006, 180(1-2), 63-70. (Pubitemid 44767709)
65. Krzysiek, R.; Lefevre, E. A.; Zou, W.; Foussat, A.; Bernard, J.; Portier, A.; Galanaud, P.; Richard, Y. Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. J. Immunol., 1999, 162(8), 4455-4463. (Pubitemid 29314842)
66. Cheifetz, A.; Mayer, L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt. Sinai J. Med., 2005, 72(4), 250-256. (Pubitemid 41052052)
67. D'Arcy, C. A.; Mannik, M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum., 2001, 44(7), 1717-1718. (Pubitemid 32642238)
68. van der Kolk, L. E.; Grillo-Lopez, A. J.; Baars, J. W.; Hack, C. E.; van Oers, M. H. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol., 2001, 115(4), 807-811. (Pubitemid 34042897)
69. Wang, S. Y.; Racila, E.; Taylor, R. P.; Weiner, G. J. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood, 2008, 111(3), 1456-1463. (Pubitemid 351213433)
70. Andersohn, F.; Konzen, C.; Garbe, E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann. Intern. Med., 2007, 146(9), 657-665. (Pubitemid 351650522)
71. Arnold, D. M.; Dentali, F.; Crowther, M. A.; Meyer, R. M.; Cook, R. J.; Sigouin, C.; Fraser, G. A.; Lim, W.; Kelton, J. G. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med., 2007, 146(1), 25-33. (Pubitemid 351650318)
72. Nitta, E.; Izutsu, K.; Sato, T.; Ota, Y.; Takeuchi, K.; Kamijo, A.; Takahashi, K.; Oshima, K.; Kanda, Y.; Chiba, S.; Motokura, T.; Kurokawa, M. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann. Oncol., 2007, 18(2), 364-369. (Pubitemid 46323107)
73. Looney, R. J.; Anolik, J. H.; Campbell, D.; Felgar, R. E.; Young, F.; Arend, L. J.; Sloand, J. A.; Rosenblatt, J.; Sanz, I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum., 2004, 50(8), 2580-2589. (Pubitemid 39062719)
74. Rituxan (package insert). In Genentech. Inc., South San Francisco, CA 2006.
75. Kotani, T.; Takeuchi, T.; Kawasaki, Y.; Hirano, S.; Tabushi, Y.; Kagitani, M.; Makino, S.; Hanafusa, T. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus, 2006, 15(10), 683-685. (Pubitemid 44682831)
76. Pijpe, J.; van Imhoff, G. W.; Spijkervet, F. K.; Roodenburg, J. L.; Wolbink, G. J.; Mansour, K.; Vissink, A.; Kallenberg, C. G.; Bootsma, H. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum., 2005, 52(9), 2740-2750. (Pubitemid 41369102)
77. Monson, N. L.; Cravens, P. D.; Frohman, E. M.; Hawker, K.; Racke, M. K. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch. Neurol., 2005, 62(2), 258-264. (Pubitemid 40204747)
78. Stuve, O.; Cepok, S.; Elias, B.; Saleh, A.; Hartung, H. P.; Hemmer, B.; Kieseier, B. C. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol., 2005, 62(10), 1620-1623. (Pubitemid 41434570)
79. Bar-Or, A.; Fawaz, L.; Fan, B.; Darlington, P. J.; Rieger, A.; Ghorayeb, C.; Calabresi, P. A.; Waubant, E.; Hauser, S. L.; Zhang, J.; Smith, C. H. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann. Neurol., 2008, 67(4), 452-461.
80. Hauser, S. L.; Waubant, E.; Arnold, D. L.; Vollmer, T.; Antel, J.; Fox, R. J.; Bar-Or, A.; Panzara, M.; Sarkar, N.; Agarwal, S.; Langer-Gould, A.; Smith, C. H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med., 2008, 358(7), 676-688. (Pubitemid 351240747)
81. Beum, P. V.; Lindorfer, M. A.; Beurskens, F.; Stukenberg, P. T.; Lokhorst, H. M.; Pawluczkowycz, A. W.; Parren, P. W.; van de Winkel, J. G.; Taylor, R. P. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol., 2008, 181(1), 822-832.
82. Cheson, B. D.; Leonard, J. P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N. Engl. J. Med., 2008, 359(6), 613-626.
83. Genc, K.; Dona, D. L.; Reder, A. T. Increased CD80 (+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J. Clin. Invest., 1997, 99(11), 2664-2671. (Pubitemid 27259813)
84. Coiffier, B.; Lepretre, S.; Pedersen, L. M.; Gadeberg, O.; Fredriksen, H.; van Oers, M. H.; Wooldridge, J.; Kloczko, J.; Holowiecki, J.; Hellmann, A.; Walewski, J.; Flensburg, M.; Petersen, J.; Robak, T. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood, 2008, 111(3), 1094-1100. (Pubitemid 351213387)
85. Frequin, S. T.; Barkhof, F.; Lamers, K. J.; Hommes, O. R.; Borm, G. F. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. Acta Neurol. Scand., 1992, 86(3), 291-297.
86. Warren, K. G.; Catz, I.; Jeffrey, V. M.; Carroll, D. J. Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations. Can. J. Neurol. Sci., 1986, 13(1), 25-30. (Pubitemid 16189885)
87. Crockard, A. D.; Treacy, M. T.; Droogan, A. G.; McNeill, T. A.; Hawkins, S. A. Transient immunomodulation by intravenous methylprednisolone treatment of multiple sclerosis. Mult. Scler. 1995, 1(1), 20-24.
88. Jiang, H.; Milo, R.; Swoveland, P.; Johnson, K. P.; Panitch, H.; Dhib-Jalbut, S. Interferon beta-1b reduces interferon gammainduced antigen-presenting capacity of human glial and B cells. J. Neuroimmunol., 1995, 61(1), 17-25.
89. Liu, Z.; Pelfrey, C. M.; Cotleur, A.; Lee, J. C.; Rudick, R. A. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J. Neuroimmunol., 2001, 112(1-2), 153-162.
90. Kim, H. J.; Ifergan, I.; Antel, J. P.; Seguin, R.; Duddy, M.; Lapierre, Y.; Jalili, F.; Bar-Or, A. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J. Immunol., 2004, 172(11), 7144-7153. (Pubitemid 38669158)
91. Chan, A.; Weilbach, F. X.; Toyka, K. V.; Gold, R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin. Exp. Immunol., 2005, 139(1), 152-158. (Pubitemid 40066141)
92. Achiron, A.; Gabbay, U.; Gilad, R.; Hassin-Baer, S.; Barak, Y.; Gornish, M.; Elizur, A.; Goldhammer, Y.; Sarova-Pinhas, I. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology, 1998, 50(2), 398-402.
93. Fazekas, F.; Deisenhammer, F.; Strasser-Fuchs, S.; Nahler, G.; Mamoli, B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet, 1997, 349(9052), 589-593. (Pubitemid 27101884)
94. Lewanska, M.; Siger-Zajdel, M.; Selmaj, K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur. J. Neurol., 2002, 9(6), 565-572. (Pubitemid 36961281)
95. Sorensen, P. S.; Wanscher, B.; Jensen, C. V.; Schreiber, K.; Blinkenberg, M.; Ravnborg, M.; Kirsmeier, H.; Larsen, V. A.; Lee, M. L. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology, 1998, 50(5), 1273-1281. (Pubitemid 28240339)
96. Fazekas, F.; Lublin, F. D.; Li, D.; Freedman, M. S.; Hartung, H. P.; Rieckmann, P.; Sorensen, P. S.; Maas-Enriquez, M.; Sommerauer, B.; Hanna, K. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology, 2008, 71(4), 265-271.
97. Alter, A.; Duddy, M.; Hebert, S.; Biernacki, K.; Prat, A.; Antel, J. P.; Yong, V. W.; Nuttall, R. K.; Pennington, C. J.; Edwards, D. R.; Bar-Or, A. Determinants of human B cell migration across brain endothelial cells. J. Immunol., 2003, 170(9), 4497-4505. (Pubitemid 36522744)
98. Niino, M.; Bodner, C.; Simard, M. L.; Alatab, S.; Gano, D.; Kim, H. J.; Trigueiro, M.; Racicot, D.; Guerette, C.; Antel, J. P.; Fournier, A.; Grand'Maison, F.; Bar-Or, A. Natalizumab effects on immune cell responses in multiple sclerosis. Ann. Neurol., 2006, 59(5), 748-754. (Pubitemid 43673152)
99. Lucchinetti, C. F.; Mandler, R. N.; McGavern, D.; Bruck, W.; Gleich, G.; Ransohoff, R. M.; Trebst, C.; Weinshenker, B.; Wingerchuk, D.; Parisi, J. E.; Lassmann, H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain, 2002, 125(Pt 7), 1450-1461. (Pubitemid 34755161)
100. Humle Jorgensen, S.; Sorensen, P. S. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J. Neurol. Sci., 2005, 233(1-2), 61-65. (Pubitemid 40804817)
101. Keegan, M.; Konig, F.; McClelland, R.; Bruck, W.; Morales, Y.; Bitsch, A.; Panitch, H.; Lassmann, H.; Weinshenker, B.; Rodriguez, M.; Parisi, J.; Lucchinetti, C. F. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet, 2005, 366(9485), 579-582. (Pubitemid 41140333)